Clicky

Ampio Pharmaceuticals, Inc.(AMPE)

Description: Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.


Keywords: Cancer Biopharmaceutical Life Sciences Diabetes Autoimmune Disease Inflammation Clinical Development Healthcare Facilities Eye Diagnostic Products Kidney Disease Diabetic Retinopathy Dysfunction Eye Diseases Metabolic Disorders Diabetic Macular Edema Diabetic Nephropathy Macular Edema Pharmaceutical Drugs Antioxidant Sexual Dysfunction Methylphenidate Inflammatory Conditions Male Sexual Dysfunction Inflammation Diseases

Home Page: www.ampiopharma.com

AMPE Technical Analysis

373 Inverness Parkway
Englewood, CO 80112
United States
Phone: 720 437 6500


Officers

Name Title
Mr. Michael A. Martino CEO & Director
Dr. David Bar-Or M.D. Founder & Chairman of Scientific Advisory Board
Mr. Daniel G. Stokely CPA, CPA CFO, Corp. Sec. & Treasurer
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. Chief Medical Officer
Lane Hapke VP of Manufacturing Operations
April Ramirez Clinical Trial Mang.
Laura Goldberg VP of Quality and Regulatory Operations

Exchange: NYSE MKT

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.2989
Price-to-Sales TTM: 0
IPO Date: 2010-03-31
Fiscal Year End: December
Full Time Employees: 9
Back to stocks